Beleodaq

Belinostat

6.7 Moderate risk

Beleodaq & Peripheral T-cell lymphoma unspecified recurrent

72.5%

of users reported Peripheral T-cell lymphoma unspecified recurrent

100.0%

also reported Severe reaction

79.3%

are men

Most common medical consequences

Severe reaction
100.0%

Have you experienced any negative side effects from this medication?

Beleodaq: general information

Most common side effects (2)